Factor IX inhibitor (antihemophilic factor B, PTC) in a woman
Hule, V.
Vnitrni Lekarstvi 21(3): 274-277
1975
ISSN/ISBN: 0042-773X PMID: 1119107 Document Number: 93993
Document emailed within 1 workday
Related Documents
Piana, L.; Magnin, G.; Sudan, J.P.; Fogliani, J.; Siccardi, F. 1972: An unusual cause of postpartum hemorrhage: the antihemophilic a factor inhibitor Revue Francaise de Gynecologie et d'Obstetrique 67(11): 621-624Zucker, M.B.; Soberano, M.E.; Johnson, A.J.; Fulton, A.J.; Kowalski, S.; Adler, M. 1983: The in vitro association of antihemophilic factor and von Willebrand factor Thrombosis and Haemostasis 49(1): 37-41
Liebe, S. 1982: Activation of the antihemophilic globulin a (factor VIII). 2. Effect of ampholine on the course of blood coagulation and the molecular conformation of factor VIIi Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 37(4): 110-116
Pfyffer, M.; Kistler, H.J.; von Felten, A. 1983: Acquired hemophilia a due to factor VIIIC inhibitor: detection of circulating immune complexes containing factor VIIIC but not factor VIIIR Schweizerische Medizinische Wochenschrift 113(40): 1456-1459
Fudge, R.P.; Vlasses, P.H. 1977: Third-party reimbursement for pharmacist instruction about antihemophilic factor American Journal of Hospital Pharmacy 34(8): 831-834
Osterud, B.; Kasper, C.K.; Lavine, K.K.; Prodanos, C.; Rapaport, S.I. 1981: Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VIi and bovine tissue factor Thrombosis and Haemostasis 45(1): 55-59
Lindhout, T.; Franssen, J.; Willems, G. 1995: Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor Thrombosis and Haemostasis 74(3): 910-915
Hofmann, V.; Ermanni, M.; Straub, P.W. 1978: Thrombin formation in factor IX concentrates and FEIBA (factor eight inhibitor bypassing activity) (proceedings) Schweizerische Medizinische Wochenschrift 108(41): 1600
Uteg, K.H.; Sander, W. 1972: Studies on cryoprecipitates. 1. Distribution of antihemophilic globulin a (factor VIII) and of thrombocytes in cryoprecipitation Folia Haematologica 97(4): 322-331
Richard, C.; Sedano, C.; Cuadrado, M.A.; Iriondo, A.; Bello, C.; Gandarillas, M.A.; Zubizarreta, A. 1986: Effect of a thymic factor on the concentration of a factor VIIi inhibitor in a patient with treated Hodgkin's disease Thrombosis and Haemostasis 55(2): 299-300
Baishev, I.M.; Zubairov, D.M. 1986: Effect of a factor XIi inhibitor isolated from kernels of corn on the cold activation of factor VIi in blood plasma Gematologiia i Transfuziologiia 31(4): 32-35
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Andresen, J.L.; Ehlers, N. 1998: Chemotaxis of human keratocytes is increased by platelet-derived growth factor-BB, epidermal growth factor, transforming growth factor-alpha, acidic fibroblast growth factor, insulin-like growth factor-I, and transforming growth factor-beta Current Eye Research 17(1): 79-87
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Tourbaf, K.D.; Dunlap, B.E.; Ambrus, J.L.; Rodman, D.J.; Atwal, A.J. 1982: The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia a patient with inhibitor Journal of Medicine 13(5-6): 399-410
Locigno, R.; Antoine, N.; Bours, V.; Daukandt, M.; Heinen, E.; Castronovo, V. 2000: TNP-470, a potent angiogenesis inhibitor, amplifies human T lymphocyte activation through an induction of nuclear factor-kappaB, nuclear factor-AT, and activation protein-1 transcription factors Laboratory Investigation; A Journal of Technical Methods and Pathology 80(1): 13-21
Almus, F.E.; Rao, L.V.; Rapaport, S.I. 1989: Functional properties of factor VIIa/tissue factor formed with purified tissue factor and with tissue factor expressed on cultured endothelial cells Thrombosis and Haemostasis 62(4): 1067-1073
Rizzino, A.; Kazakoff, P.; Ruff, E.; Kuszynski, C.; Nebelsick, J. 1988: Regulatory effects of cell density on the binding of transforming growth factor beta, epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor Cancer Research 48(15): 4266-4271
Sugihara, T.; Saito, H. 1987: Application of a monoclonal antibody against factor XIi (Hageman factor); enzyme-linked immunosorbent assay (ELISA) for factor XIi antigen Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 50(3): 691-695